Top

Published in:

Open Access 01-12-2012 | PRECLINICAL STUDIES

Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas

Authors: Angela Ruban, Tamara Berkutzki, Itzik Cooper, Boaz Mohar, Vivian I. Teichberg

Published in: Investigational New Drugs | Issue 6/2012

Summary

L-Glutamate (Glu) plays a crucial role in the growth of malignant gliomas. We have established the feasibility of accelerating a naturally occurring brain to-blood Glu efflux by decreasing blood Glu levels with intravenous oxaloacetate, the respective Glu co-substrate of the blood resident enzyme humane glutamate–oxaloacetate transaminase (hGOT). We wished to demonstrate that blood Glu scavenging provides neuroprotection in the case of glioma. We now describe the neuroprotective effects of blood Glu scavenging in a fatal condition such as brain-implanted C6 glioma in rats and brain-implanted human U87 MG glioma in nude mice. Rat (C-6) or human (U87) glioma cells were grafted stereotactically in the brain of rats or mice. After development of tumors, the animals were drinking oxaloacetate with or without injections of hGOT. In addition, mice were treated with combination treatment, which included drinking oxaloacetate with intracutaneous injections of hGOT and intraperitoneal injection of Temozolomide. Animals drinking oxaloacetate with or without injections of hGOT displayed a smaller tumor volume, reduced invasiveness and prolonged survival than control animals drinking saline. These effects were significantly enhanced by Temozolomide in mice, which increased survival by 237%. This is the first demonstration of blood Glu scavenging in brain cancer, and because of its safety, is likely to be of clinical significance for the future treatment of human gliomas. As we demonstrated, the blood glutamate scavenging treatment in combination with TMZ could be a good candidate or as an alternative treatment to the patients that do not respond to TMZ.

de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59(8):1181–1189PubMedCrossRef

Sontheimer H (2003) Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 26(10):543–549PubMedCrossRef

Sontheimer H (2004) Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol 29(1):61–71PubMedCrossRef

Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383–4391PubMed

Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19(24):10767–10777PubMed

Behrens PF et al (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47(1):11–22PubMedCrossRef

Rijpkema M et al (2003) Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16(1):12–18PubMedCrossRef

Roslin M et al (2003) Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61(2):151–160PubMedCrossRef

Chung WJ et al (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25(31):7101–7110PubMedCrossRef

10.

Takano T et al (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010–1015PubMedCrossRef

11.

Ishiuchi S et al (2007) Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27(30):7987–8001PubMedCrossRef

12.

Arcella A et al (2005) Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7(3):236–245PubMedCrossRef

13.

Ishiuchi S et al (2002) Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8(9):971–978PubMedCrossRef

14.

Lyons SA et al (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463–9471PubMedCrossRef

15.

Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1(6):383–386PubMedCrossRef

16.

Cohen-Kashi-Malina K, Cooper I and Teichberg VI Mechanisms of glutamate efflux at the blood-brain barrier: involvement of glial cells. J Cereb Blood Flow Metab

17.

Teichberg VI et al (2009) Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience 158(1):301–308PubMedCrossRef

18.

Berl S, Lajtha A, Waelsch H (1961) Amino acid and protein metabolism of the brain. VI. Cerebral compartments of glutamic acid metabolism. J Neurochem 7:186–197CrossRef

19.

Gottlieb M, Wang Y, Teichberg VI (2003) Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 87(1):119–126PubMedCrossRef

20.

Zlotnik A et al (2009) The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 21(3):235–241PubMedCrossRef

21.

Zlotnik A et al (2008) The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 33(6):1044–1050PubMedCrossRef

22.

Zlotnik A et al (2007) Brain neuroprotection by scavenging blood glutamate. Exp Neurol 203(1):213–220PubMedCrossRef

23.

Campos F, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab

24.

Philip M et al (2009) Methodological quality of animal studies of neuroprotective agents currently in phases II/III acute ischemic stroke trials. Stroke 40(2):577–581PubMedCrossRef

25.

Campos F, et al. (2011) High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab published on line

26.

Castillo J et al (1996) Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27(6):1060–1065PubMedCrossRef

27.

Burckhardt BC et al (2005) Substrate specificity of the human renal sodium dicarboxylate cotransporter, hNaDC-3, under voltage-clamp conditions. Am J Physiol Renal Physiol 288(4):F792–F799PubMedCrossRef

28.

Pajor AM, Gangula R, Yao X (2001) Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotransporter from mouse brain. Am J Physiol Cell Physiol 280(5):C1215–C1223PubMed

29.

Haussinger D et al (1989) Hepatocytes heterogeneity in glutamate metabolism and bidirectional transport in perfused rat liver. Eur J Biochem 185(1):189–195PubMedCrossRef

30.

Kollareddy M et al (2008) Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152(1):27–33PubMedCrossRef

31.

Loh JK, et al. Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer 10: p 268

32.

Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3(5):430–446PubMedCrossRef

33.

Oka A et al (1993) Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 13(4):1441–1453PubMed

34.

Augustine CK et al (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15(2):502–510PubMedCrossRef

35.

Ma D, Rajakumaraswamy N, Maze M (2004) alpha2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull 71:77–92PubMedCrossRef

Title: Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas
Authors: Angela Ruban
Tamara Berkutzki
Itzik Cooper
Boaz Mohar
Vivian I. Teichberg
Publication date: 01-12-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 6/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-012-9794-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 6/2012

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer